Abbott Amidate shortage
Executive Summary
Abbott files sNDA requesting approval for use of alternate supplier for Amidate active ingredient etomidate. Company announces shortage of anesthetic in June 18 "Dear Clinician" letter. "Our approved supplier of the active pharmaceutical ingredient has exited the market," letter says. "Clinicians are requested to utilize Amidate judiciously for the interim period of time until Abbott is able to manufacture sufficient inventory to once again meet the market demands." Shortages of another anesthetic, fentanyl, prompted Abbott to double its own production last year (1"The Pink Sheet" March 21, 2001, p. 16)...
You may also be interested in...
Abbott Doubles Fentanyl Production To Address Hospital Shortages
Abbott has doubled the production of fentanyl to respond to supply shortages of the anesthetic in hospitals around the country, the company said.
RB Doubles R&D Spend In Search Of 'Game Changing’ OTC Innovation
With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.
JHL Becomes Eden And Announces Denosumab Progress
Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: